Alpha Tau Medical Ltd (DRTS) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

Jul 10, 2026

43/ 100

GoAI Score

Hold

Valuation

32

Expensive

Sentiment

50

Mixed

Risk

47

Elevated Risk

Momentum

71

Gaining

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

Company profile

Company website

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.

Industry: Biotechnology
Sector: Healthcare
Headquarters: IL
CEO: Uzi Sofer
Listed since: Mar 8, 2021
Employees: 121

Market position

Day range

Current $14.41

$14.00$14.50

52-week range

Current $14.41

$3.43$15.79

Open: $14.00
Previous close: $14.00
Volume: 368.03K; 0.54× average
Average volume: 675.64K; Average daily volume
Market cap: 1.3B USD
Beta: 1.22; Market reference 1
50-day average: $14.3726; +0.26% above average
200-day average: $10.039; +43.54% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 396.63M USD
P/E (TTM): -13.86×
P/B (TTM): 29.75×
P/S (TTM): 0×
EV / EBITDA: -9.66×
Earnings yield: -10.69%
Free cash flow yield: -8.21%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: -55.29%
Return on assets: -40.00%
Return on invested capital: -43.50%

Financial health

Debt / equity: 0.34×
Current ratio: 7.45×
Altman Z-score: 5.59
Piotroski F-score: 2 of 9

Financial statements

Income trends

Operating income

−42.29M USD-17.33%

Net income

−42.63M USD-34.26%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Cost of goods sold	1.23M USD	—	—	—	—
Gross profit	−1.23M USD	—	—	—	—
Research and development	30.83M USD	27.02M USD	26.42M USD	20.89M USD	11.45M USD
Selling, general, and administrative	10.22M USD	9.02M USD	9.26M USD	11.25M USD	2.34M USD
Operating expenses	41.06M USD	36.04M USD	35.68M USD	32.14M USD	13.79M USD
Interest income	3.84M USD	4.28M USD	4.83M USD	1.79M USD	211K USD
Interest expense	419K USD	303K USD	75K USD	—	—
Depreciation and amortization	1.23M USD	1.1M USD	1.07M USD	979K USD	776K USD
Operating income	−42.29M USD	−36.04M USD	−35.68M USD	−32.14M USD	−13.79M USD
Net income	−42.63M USD	−31.75M USD	−29.16M USD	−33.76M USD	−27.27M USD

Company facts updated Oct 10, 2026.

Earnings

EPS beat rate: 40%; 4 beats, 5 misses, 1 met estimate
Average EPS surprise: -32.72%; 10 comparable reports
Latest EPS result: -0.5; Estimate -0.14 · Miss by 254.91%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$18.00

24.91% upside

Past 12 months12-month forecastHigh $30.00Average $18.00Low $8.00

Rating distribution

6 ratings

Strong buy00%

Buy583%

Hold117%

Sell00%

Strong sell00%

DRTS news

globenewswire.comOct 5, 2026

Alpha Tau to Participate in October Investor Conferences

JERUSALEM, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that…

Read source

seekingalpha.comSep 11, 2026

Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More

Oramed Pharmaceuticals Inc. maintains a Hold rating as it pivots from drug development to strategic investments, with significant progress in asset growth and portfolio diversification. ORMP's investments in Lifeward and…

Read source

seekingalpha.comSep 4, 2026

Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough

Alpha Tau is positioned for a transformative inflection point with potentially groundbreaking GBM data expected before year-end and pancreatic shortly after. Two out of first three GBM patients achieved a complete…

Read source

globenewswire.comSep 2, 2026

Alpha Tau to Participate in September Investor Conferences

JERUSALEM, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd.

Read source

globenewswire.comAug 31, 2026

Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions

- IMPACT, a multicenter pilot study of Alpha DaRT ® for newly diagnosed unresectable pancreatic cancer, expanded enrollment three times over the course of the study, from an original enrollment of 12 patients to a total…

Read source

defenseworld.netAug 13, 2026

PAVmed (NASDAQ:PAVM) versus Alpha Tau Medical (NASDAQ:DRTS) Critical Contrast

PAVmed (NASDAQ: PAVM - Get Free Report) and Alpha Tau Medical (NASDAQ: DRTS - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the…

Read source